Happy Ring at United States (multiple hotel chains)

Happy Ring is a finger-worn smart ring made by Happy Health Inc of Austin, Texas, and it is recorded in the biometric form factor as the within-cohort genuinely-FDA-cleared sleep-apnea exemplar, the verified counterpoint to uncleared sleep-apnea claims elsewhere in the cohort. Its sensor stack of four LEDs, four electrodes, a three-axis accelerometer, and two temperature sensors yields heart rate, heart-rate variability, blood-oxygen saturation, skin temperature, respiratory rate, activity, and sleep staging, and the value of the device is its cleared sleep-apnea algorithm.

It holds two FDA 510(k) clearances: K240236, decided October 8, 2024, for retrospective remote monitoring of physiological parameters in adults at home or in healthcare facilities, and K242224, decided June 18, 2025, a Home Sleep Test that processes ring signals for clinician-interpreted diagnosis of sleep disorders such as obstructive sleep apnea and insomnia in individuals aged twenty-two and older under the direction of a trained healthcare provider. The first clearance is best read as monitoring and the second as diagnosis-facilitating, so the genuinely-FDA-cleared framing holds while the diagnosis is clinician-mediated rather than autonomous, and the registry does not extend the claim beyond the cleared indication.

Several cap-flags apply. The widely-cited figure of about ninety-seven percent agreement with gold-standard polysomnography is company-reported and has no peer-reviewed citation found, with the company's own technology page instead stating the softer claim of being ten times more accurate than a watch. Commercial availability is service-gated and thin: the ring is sold only bundled into the clinician-reviewed Happy Sleep home-sleep-test service, which is insurer-billed, rather than as a standalone retail ring with a published consumer price, and the company raised a sixty-million-dollar Series A in August 2022 led by ARCH Venture Partners with no later round surfaced, so it is an early-stage and quiet company; the maturity is recorded as commercial because the cleared service is live and billed, with the cap-flag preventing over-reading the FDA clearance as broad market presence.

Finally, marketing references to brain activity or brain biometrics are flagged as marketing-forward because no EEG sensor is itemized on the spec page. The chief executive is Dustin Freckleton, MD.